Get the Stockscreener App
0.4096
2.53%
0.0101
Biorestorative Therapies Inc stock is traded at $0.4096, with a volume of 584.21K.
It is up +2.53% in the last 24 hours and up +119.51% over the past month.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
See More
Previous Close:
$0.3995
Open:
$0.37
24h Volume:
584.21K
Relative Volume:
0.06
Market Cap:
$10.44M
Revenue:
$357.90K
Net Income/Loss:
$-11.06M
P/E Ratio:
-0.3657
EPS:
-1.1201
Net Cash Flow:
$-11.90M
1W Performance:
+8.94%
1M Performance:
+119.51%
6M Performance:
-65.29%
1Y Performance:
-75.91%
1-Day Range:
$0.37
$0.4099
1-Week Range:
$0.3496
$0.42
52-Week Range:
$0.1593
$1.89
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Name
Biorestorative Therapies Inc
Sector
Industry
Phone
(631) 760-8100
Address
40 MARCUS DRIVE, MELVILLE
Compare BRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
0.4096 | 10.44M | 357.90K | -11.06M | -11.90M | -1.1201 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biorestorative Therapies Inc Stock (BRTX) Latest News
Director Mika Grasso files initial Form 3 at BioRestorative (BRTX) - Stock Titan
BioRestorative Therapies (NASDAQ: BRTX) director Dhaliwal files clean Form 3 - Stock Titan
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth - The Manila Times
BioRestorative Therapies Appoints Zachary Smith as Vice President of Biocosmeceuticals Division - Quiver Quantitative
BioRestorative Therapies Inc (BRTX) Institutional Confidence - TradingKey
BioRestorative Therapies (BRTX) director Katharyn Field files initial Form 3 - Stock Titan
BioRestorative Therapies Inc - TradingKey
BioRestorative Therapies Inc (BRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioRestorative Therapies Inc (BRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioRestorative Therapies Inc (BRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Discontinued operations of BioRestorative Therapies, Inc. – DUS:9OF - TradingView
BioRestorative Therapies, Inc. Cash Flow – DUS:9OF - TradingView
BioRestorative Therapies, Inc. Revenue Breakdown – DUS:9OF - TradingView
BioRestorative Therapies Inc (BRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BRTX News | BIORESTORATIVE THERAPIES INC (NASDAQ:BRTX) - ChartMill
BioRestorative Therapies, Inc. Enters Revolving Credit Agreement with Bowery Group LLC – 12% Interest, NASDAQ: BRTX – Minichart - Minichart
BioRestorative Revamps Board Following New Loan Agreement - TipRanks
BioRestorative Therapies Finalizes Executive Agreement with R&D VP - TipRanks
BioRestorative Therapies enters $1 million revolving loan and appoints new directors - Investing.com Nigeria
BioRestorative (NASDAQ: BRTX) sets 3-year deal with R&D leader Silva - Stock Titan
BioRestorative Therapies, Inc. Enters Into $1,000,000 Revolving Loan Agreement With Bowery Group LLC - marketscreener.com
BioRestorative Therapies (NASDAQ: BRTX) adds $1M revolver and installs lender-backed directors - Stock Titan
BRTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Cash Management ContinuesEarnings Season Outlook - newsline.com
BioRestorative Therapies Inc. (BRTX) Q1 2026 Earnings: Narrowing Losses Drive Strong Stock SurgeRevenue Miss Report - newsline.com
BRTX Stock Price, Quote & Chart | BIORESTORATIVE THERAPIES INC (NASDAQ:BRTX) - ChartMill
BioRestorative Therapies Executive Employment Agreement with Lance Alstodt: Key Terms, Compensation, and Severance Details - Minichart
BioRestorative Therapies Extends Executive Leadership Employment Agreements - TipRanks
BioRestorative Therapies extends employment agreements for Lance Alstodt and Robert Kristal - TradingView
BioRestorative Therapies (BRTX) triples down on stock capacity and inks new CEO, CFO contracts - Stock Titan
BioRestorative Therapies jumps after completing Phase 2 dosing for lead spine cell therapy - Quiver Quantitative
BioRestorative Therapies stock surges on activist stake By Investing.com - Investing.com South Africa
BioRestorative Therapies stock surges on activist stake - Investing.com
Kaos Capital is urgently seeking a meeting with the Board of Directors of BioRestorative Therapies, Inc. (BioRestorative Therapies) to explore effective ways to unlock shareholder value for the company. - Bitget
Kaos Capital acquires 4.9% stake in BioRestorative Therapies - marketscreener.com
Kaos Capital Acquires 4.9% Stake In Biorestorative Therapies - TradingView
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) - marketscreener.com
Press Release: Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) - Moomoo
Biorestorative Therapies says topline phase 2 data for BRTX-100 expected in Q2 2027 - marketscreener.com
Biorestorative Therapies Says Topline Phase 2 Data For BRTX-100 Expected In Q2 2027 - TradingView
BioRestorative Therapies Completes Patient Dosing in Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease - Quiver Quantitative
Stem cell back pain shot finishes Phase 2, topline data due 2027 - Stock Titan
BioRestorative Therapies Inc. (BRTX) Q1 2026 Earnings: Narrower Loss Surprises, Stock Rises 7.8%Final Results - The Legal Advocate
BRTX Q1 2026 Earnings: Narrowed Loss Surprises, Shares Climb 7.8%Earnings Beat Alert - newsline.com
BioRestorative Therapies (BRTX) Surges 13.66% as Stock Tests Key Resistance at $0.20Corrective Wave - Newser
What makes Biorestorative Therapies (BRTX) a new buy stock - MSN
Biorestorative Therapies, Inc. (BRTX) reports Q1 loss, misses revenue estimates - MSN
Auctus Fund (BRTX) discloses 2.7M-share, 9.9% position including warrants - Stock Titan
What Makes Biorestorative Therapies (BRTX) a New Buy Stock - Yahoo Finance
MSN Money - MSN
Certain Series B Preferred Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Certain Warrants of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Biorestorative Therapies Inc Stock (BRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):